272 related articles for article (PubMed ID: 27931793)
41. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
MacVane SH; Pandey R; Steed LL; Kreiswirth BN; Chen L
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
[TBL] [Abstract][Full Text] [Related]
42. Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
Shortridge D; Duncan LR; Pfaller MA; Flamm RK
Int J Antimicrob Agents; 2019 May; 53(5):637-643. PubMed ID: 30716448
[TBL] [Abstract][Full Text] [Related]
43. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Xiao AJ; Huntington JA; Long J; Caro L
Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
[TBL] [Abstract][Full Text] [Related]
44. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
45. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
[TBL] [Abstract][Full Text] [Related]
46. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
47. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Maseda E; Aguilar L; Gimenez MJ; Gilsanz F
Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1311-24. PubMed ID: 25139127
[TBL] [Abstract][Full Text] [Related]
48. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.
Estabrook M; Bussell B; Clugston SL; Bush K
J Clin Microbiol; 2014 Nov; 52(11):4049-52. PubMed ID: 25143578
[TBL] [Abstract][Full Text] [Related]
49. Killing of Escherichia coli by beta-lactams at different inocula.
Tam VH; Ledesma KR; Chang KT; Wang TY; Quinn JP
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):166-71. PubMed ID: 19304437
[TBL] [Abstract][Full Text] [Related]
50. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Farrell DJ; Sader HS; Flamm RK; Jones RN
Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
[TBL] [Abstract][Full Text] [Related]
51. ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!
Teleb M; Soto-Ruiz E; Dominguez DC; Antony S
Infect Disord Drug Targets; 2018; 18(1):81-85. PubMed ID: 27411471
[TBL] [Abstract][Full Text] [Related]
52. [Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].
Žemličková H; Jakubů V; Fridrichová M
Klin Mikrobiol Infekc Lek; 2017 Dec; 23(4):132-135. PubMed ID: 29378381
[TBL] [Abstract][Full Text] [Related]
53. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
54. Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Castaldo N; Givone F; Peghin M; Righi E; Sartor A; Bassetti M
J Glob Antimicrob Resist; 2017 Jun; 9():100-102. PubMed ID: 28495526
[TBL] [Abstract][Full Text] [Related]
55. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.
Ambrose PG; VanScoy BD; Trang M; McCauley-Miller J; Conde H; Bhavnani SM; Alexander DC; Friedrich LV
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947474
[TBL] [Abstract][Full Text] [Related]
57. CTX-M-190, a Novel β-Lactamase Resistant to Tazobactam and Sulbactam, Identified in an Escherichia coli Clinical Isolate.
Shen Z; Ding B; Bi Y; Wu S; Xu S; Xu X; Guo Q; Wang M
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821452
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
[TBL] [Abstract][Full Text] [Related]
59. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Melchers MJ; Mavridou E; Seyedmousavi S; van Mil AC; Lagarde C; Mouton JW
Antimicrob Agents Chemother; 2015; 59(6):3373-6. PubMed ID: 25824214
[TBL] [Abstract][Full Text] [Related]
60. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
